



9th March 2011

Company's Announcement Office
ASX Limited
Exchange Centre
20 Bridge Street
Sydney NSW 2000

ASX ANNOUNCEMENT / MEDIA RELEASE

European patent allowed for Mix&Go™ IP

- **Patent protects Anteo's intellectual property in a large market**
- **Patent has 12 years to run**
- **Australian application for this patent already granted**
- **Additional patents for IP on new technology to be filed shortly**

Sydney 9th March 2011: Anteo Diagnostics Limited (ASX:ADO) is pleased to announce that the European Patent Office has issued confirmation that it intends to grant the "Generation of Surface Coating Diversity" patent to the Company.

This means that a patent will shortly be granted to Anteo to protect the intellectual property that led to the discovery of the Mix&Go™ technology. This ensures that the process that was used to bind antibodies to more than 8,000 different types of surfaces cannot be copied in the European market.

Also, additional screening exercises that could be initiated to identify new "glues" for a broad range of other industries and sectors will also be covered under this patent which has a 12-year life. The patent was filed in 2003, and given a 20-year life, is due to expire in 2023.

The patent has already been granted in Australia and Anteo is currently waiting on it being granted in additional markets.

Another family of patents has been filed to protect Mix&Go™ and further patents, intended to protect more recent innovations to Mix&Go™ technology, are scheduled to be filed in 2nd quarter 2011.

Anteo's Managing Director Dr. Geoff Cumming said: "This is a very pleasing and important development for the company, and it underpins the value of the intellectual property that led to the discovery of our Mix&Go™ technology."

Anteo Diagnostics Limited ABN 75 070 028 625

Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

Phone 07 3219 0085 **Fax** 07 3219 0553 **Email** contact@anteodx.com **Web** www.anteodx.com

For personal use only



“A key highlight of this development is that the patent covers additional screening exercises that could be initiated to identify glues for new applications. This ensures that our intellectual property is protected across a range of other sectors where the technology is applicable.

“As we have previously advised, the Mix&Go™ technology can be applied to a broad number of sectors outside of healthcare and this presents significant future upside for ADO.

“ADO is making good progress in the healthcare sector with a wide range of companies actively assessing the technology. We will update shareholders on new agreements as they unfold.”

ENDS

For further information please contact:

Dr Geoff Cumming, CEO, Anteo Diagnostics Limited

Tel: +612 8823 3110

Mr James Henderson, Non Executive Chairman, Anteo Diagnostics Limited

Tel: +612 8823 3100

Anteo Diagnostics Limited ABN 75 070 028 625

Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

Phone 07 3219 0085 **Fax** 07 3219 0553 **Email** contact@anteodx.com **Web** www.anteodx.com

For personal use only